12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vanlev omapatrilat inhibitor of angiotensin-converting enzyme and neutral endopeptidase regulatory update

BMY withdrew its NDA for Vanlev to treat hypertension in response to questions raised by the FDA regarding...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >